RUNX1-RUNX1T1 fusion
|
AML
|
RUNX1-RUNX1T1 fusion
|
AML
|
gemtuzumab ozogamicin Sensitive: A2 - Guideline
|
gemtuzumab ozogamicin Sensitive: A2 - Guideline
|
RUNX1-RUNX1T1 fusion
|
AML
|
RUNX1-RUNX1T1 fusion
|
AML
|
dasatinib Sensitive: C2 – Inclusion Criteria
|
dasatinib Sensitive: C2 – Inclusion Criteria
|
RUNX1-RUNX1T1 fusion
|
AML
|
RUNX1-RUNX1T1 fusion
|
AML
|
DA Sensitive: C3 – Early Trials
|
DA Sensitive: C3 – Early Trials
|